|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we synthesized a novel tumor targeting system by using two key elements: (1) Bld-1 peptide (SNRDARRC), a recently reported bladder tumor targeting peptide identified by using a phage-displayed peptide library, and (2) ELP, a thermally responsive polypeptide.
|
29497090 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings support the hypothesis that Transcription Factor 21 is a regulator of steroidogenic factor 1 and is a tumor suppressor gene in pediatric and adult adrenocortical tumors.
|
28658440 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumour was positive for adrenocorticotropic hormone, chromogranin A (CGA), and steroidogenic factor-1 (SF-1) on the tumour surface.
|
28193212 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HSP90 was downregulated by TCCP by inactivation of HSF-1 resulting in inhibition of tumor cell proliferation, VEGF-induced cell migration, and concomitant decrease in tumor burden and neo-angiogenesis in vivo.
|
28717943 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To optimize FKBP/Rapa for subcutaneous (SC) administration, this manuscript expands upon first-generation FSI nanoparticles (<i>R<sub>h</sub></i> ~ 25 nm) and compares them with two second-generation carriers (FA and FAF) that: i) do not self-assemble; ii) retain a hydrodynamic radius (<i>R<sub>h</sub></i> ~ 7 nm) above the renal filtration cutoff; iii) increase tumor accumulation; and iv) have either one (FA) or two (FAF) drug-binding FKBP domains per ELP protein.
|
29109782 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Single intraperitoneal injection of the RGD-TRAIL-ELP nanoparticle induced nearly complete tumor regression in the COLO-205 tumor xenograft model.
|
28225020 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genotyping of three NR5A1 SNPs in matched tumor/normal tissues identified LOH in 16/36 (44%) of the ovarian tumors successfully analyzed, and somatic mutations (gain of allele) in 10% of the tumors.
|
23291911 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Steroidogenic Factor-1 (SF-1) is a nuclear receptor that has a pivotal role in the development of adrenal glands and gonads and in the control of steroid hormone production, being also implicated in the pathogenesis of adrenocortical tumors.
|
23907384 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, SF-1 expression was absent in all nonsteroidogenic tumors.
|
20660055 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, a strong SF-1 staining was identified in five (29%) pediatric adrenocortical tumors without SF-1 amplification.
|
20080844 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors.
|
15546904 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No new mutations were found.The frequencies of two previously described linked polymorphisms, one a change of -344C to T in a putative steroidogenic factor-1 (SF-1) binding site and the other an exchange of intron 2 for that of CYP11B1 (conversion) were measured in tumour and genomic DNA.
|
11422106 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, tumor Pit-1 mRNA positively correlates with GH, PRL and TSH beta mRNA while tumor SF-1 mRNA correlates well with FSH beta mRNA.
|
11081157 |
1999 |